CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects, best way to give, and best dose of CCI-779
and EKB-569 in treating patients with advanced solid tumors. Drugs used in chemotherapy, such
as CCI-779, work in different ways to stop the growth of tumor cells, either by killing the
cells or by stopping them from dividing. EKB-569 may stop the growth of tumor cells by
blocking some of the enzymes needed for their growth. Giving CCI-779 together with EKB-569
may kill more tumor cells.